TearLab Corp. (NASDAQ:TEAR) – Analysts at Roth Capital dropped their Q4 2016 earnings estimates for shares of TearLab Corp. in a report issued on Monday. Roth Capital analyst C. Lewis now expects that the brokerage will post earnings per share of ($0.09) for the quarter, down from their previous forecast of ($0.08). Roth Capital has a “Neutral” rating on the stock. Roth Capital also issued estimates for TearLab Corp.’s Q1 2017 earnings at ($0.05) EPS and Q4 2017 earnings at ($0.05) EPS.

Several other brokerages have also commented on TEAR. Zacks Investment Research raised TearLab Corp. from a “sell” rating to a “hold” rating in a research note on Tuesday, September 6th. Rodman & Renshaw reiterated a “buy” rating and set a $2.00 target price on shares of TearLab Corp. in a report on Saturday, October 15th. Finally, HC Wainwright set a $2.00 target price on TearLab Corp. and gave the company a “buy” rating in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. TearLab Corp. presently has a consensus rating of “Buy” and a consensus price target of $2.20.

Earnings History and Estimates for TearLab Corp. (NASDAQ:TEAR)

TearLab Corp. (NASDAQ:TEAR) opened at 0.56 on Wednesday. The stock’s 50 day moving average price is $0.64 and its 200 day moving average price is $0.72. TearLab Corp. has a 52-week low of $0.55 and a 52-week high of $1.93. The stock’s market capitalization is $29.62 million.

TearLab Corp. (NASDAQ:TEAR) last released its quarterly earnings results on Monday, November 7th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. The firm had revenue of $20.90 million for the quarter, compared to analysts’ expectations of $7.13 million. During the same quarter in the prior year, the business earned ($0.24) earnings per share. The company’s quarterly revenue was up 9.1% on a year-over-year basis.

Several hedge funds and other institutional investors have recently modified their holdings of TEAR. Vanguard Group Inc. raised its position in shares of TearLab Corp. by 0.4% in the second quarter. Vanguard Group Inc. now owns 825,984 shares of the company’s stock worth $528,000 after buying an additional 3,100 shares in the last quarter. Perkins Capital Management Inc. raised its position in shares of TearLab Corp. by 38.0% in the second quarter. Perkins Capital Management Inc. now owns 1,755,242 shares of the company’s stock worth $1,123,000 after buying an additional 483,500 shares in the last quarter. Sabby Management LLC acquired a new position in shares of TearLab Corp. during the second quarter worth $1,205,000. First Light Asset Management LLC raised its position in shares of TearLab Corp. by 0.4% in the second quarter. First Light Asset Management LLC now owns 3,760,430 shares of the company’s stock worth $2,407,000 after buying an additional 14,267 shares in the last quarter. Finally, AWM Investment Company Inc. acquired a new position in shares of TearLab Corp. during the second quarter worth $3,377,000. 38.50% of the stock is currently owned by institutional investors.

About TearLab Corp.

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.

5 Day Chart for NASDAQ:TEAR

Receive News & Stock Ratings for TearLab Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corp. and related stocks with our FREE daily email newsletter.